复方樟柳碱注射液治疗中心凹旁型中浆病

Treatment of juxtafoveal central serous chorioretinopathy by compound anisodine injection

目的：观察复方樟柳碱注射液治疗中心凹旁型中心性浆液性脉络膜视网膜病变（ CSC ，简称中浆病）的临床疗效和安全性。 方法：将60例60眼确诊为中心凹旁型CSC患者随机分为治疗组32例32眼和对照组28例28眼，治疗组采用复方樟柳碱注射液2 mL，予患眼侧颞浅动脉旁皮下注射，每日1次，对照组给予传统药物口服治疗，疗程均为2～4个疗程。以患者最佳矫正视力（ BCVA ）、自觉症状、视野、平均光敏感度及OCT结果为主要观察指标。 结果：治疗前两组各指标无显著性差异（P＞0．05），治疗后1，3mo治疗组各项指标均比对照组显著好转（ P＜0．05），治疗后6mo两组之间均无显著性差异（ P＞0．05）。治疗组除个别患者有短暂口干、头晕及心慌外，未发现严重不良反应。 结论：复方樟柳碱注射液治疗中心凹旁型CSC患者的效果明显，可缩短病程，改善视功能，降低复发率。

AIM： To investigate the efficiency and security of compound anisodine injection in the treatment of juxtafoveal central serous chorioretinopathy （ CSC） . METHODS： Sixty patients （ 60 eyes ） who were diagnosed of juxtafoveal CSC were assigned randomly into 2 groups：32 cases （32 eyes, therapeutic group） were injected subcutaneously compound anisodine injection for 2mL q.d around superficial temporal arteries in the affected eyes;28 cases （28 eyes, control group） received only traditional oral medication. Both groups received therapy for 2 to 4 courses of treatment. The main observations were the best corrected visual acuity （ BCVA） , subjective symptom, visual field, average light sensitivity and optical coherent topography （ OCT） . RESULTS： There was no significant difference between the therapeutic group and the control group before treatment （P〉0.05）, but all the outcome measures at 1, 3mo in the treatment group were significantly improved as compared with control group （ P〈0.05）.After 6mo, there were no significant difference between the two groups in all measures （ P〉0.05 ）.No severe adverse reaction was noted except mild ones such as temporary dry mouth, dizziness and palpitation in a few cases. CONCLUSION： Compound anisodine injection has remarkable effects in the treatment of juxtafoveal CSC.It can shorten the course, improved the visual function and decreased the recurrence rate of CSC.